Notice: This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TROV vs. VXRT, OTLK, INMB, FENC, ALVR, IVVD, ELUT, IPSC, BCAB, and CLLSShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Vaxart (VXRT), Outlook Therapeutics (OTLK), INmune Bio (INMB), Fennec Pharmaceuticals (FENC), AlloVir (ALVR), Invivyd (IVVD), Elutia (ELUT), Century Therapeutics (IPSC), BioAtla (BCAB), and Cellectis (CLLS). These companies are all part of the "medical" sector. Cardiff Oncology vs. Vaxart Outlook Therapeutics INmune Bio Fennec Pharmaceuticals AlloVir Invivyd Elutia Century Therapeutics BioAtla Cellectis Vaxart (NASDAQ:VXRT) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends. Does the media favor VXRT or TROV? In the previous week, Vaxart and Vaxart both had 1 articles in the media. Vaxart's average media sentiment score of 0.67 beat Cardiff Oncology's score of 0.00 indicating that Vaxart is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxart 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, VXRT or TROV? Cardiff Oncology has lower revenue, but higher earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$15.65M8.73-$82.46M-$0.46-1.67Cardiff Oncology$250K141.16-$16.41M-$2.80-1.14 Do analysts rate VXRT or TROV? Vaxart presently has a consensus target price of $3.00, indicating a potential upside of 289.66%. Given Vaxart's higher possible upside, equities research analysts plainly believe Vaxart is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community favor VXRT or TROV? Cardiff Oncology received 92 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 65.54% of users gave Vaxart an outperform vote. CompanyUnderperformOutperformVaxartOutperform Votes31065.54% Underperform Votes16334.46% Cardiff OncologyOutperform Votes40273.09% Underperform Votes14826.91% Do institutionals and insiders hold more shares of VXRT or TROV? 18.0% of Vaxart shares are owned by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are owned by institutional investors. 2.6% of Vaxart shares are owned by company insiders. Comparatively, 0.6% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is VXRT or TROV more profitable? Vaxart has a net margin of -543.21% compared to Cardiff Oncology's net margin of -3,688.31%. Vaxart's return on equity of -114.19% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-543.21% -114.19% -75.68% Cardiff Oncology -3,688.31%-202.00%-122.92% Which has more risk & volatility, VXRT or TROV? Vaxart has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. SummaryVaxart beats Cardiff Oncology on 10 of the 16 factors compared between the two stocks. Ad Timothy SykesCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.29M$3.13B$5.40B$8.53BDividend YieldN/A1.77%5.15%4.14%P/E Ratio-1.0611.58112.5515.07Price / Sales141.16331.231,478.8293.55Price / CashN/A148.6339.8334.04Price / Book3.414.024.645.01Net Income-$16.41M-$42.25M$119.13M$225.46M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$3.21+2.6%N/A+197.1%$35.29M$250,000.00-1.06N/ANews CoverageVXRTVaxart1.8928 of 5 stars$0.77flat$3.00+289.7%+19.2%$136.60M$15.65M-1.67109Upcoming EarningsNews CoverageOTLKOutlook Therapeutics1.5922 of 5 stars$6.05+5.0%$48.20+696.7%-52.2%$136.26MN/A-0.5720INMBINmune Bio2.322 of 5 stars$6.04+3.2%$20.00+231.1%-14.6%$119.35M$160,000.00-2.9310Short Interest ↑News CoverageFENCFennec Pharmaceuticals2.8112 of 5 stars$4.34-0.5%$14.00+222.6%-35.6%$119.01M$48.89M108.53N/AUpcoming EarningsNews CoverageALVRAlloVir2.5634 of 5 stars$0.95+2.1%N/A-38.1%$109.98MN/A-0.78110Upcoming EarningsShort Interest ↓News CoveragePositive NewsIVVDInvivyd2.4695 of 5 stars$0.91+2.2%$11.33+1,140.5%-37.9%$109.12MN/A-0.50100Analyst ForecastNews CoverageELUTElutia2.7821 of 5 stars$3.19-0.3%$10.00+213.5%+141.7%$108.65M$24.99M-1.12180Short Interest ↑News CoverageIPSCCentury Therapeutics1.7535 of 5 stars$1.26+9.6%$12.75+911.9%-15.4%$106.75M$2.23M-0.62170BCABBioAtla2.1078 of 5 stars$2.09+8.9%$6.00+187.1%+37.5%$101.03M$250,000.00-0.9660Upcoming EarningsNews CoverageCLLSCellectis2.5045 of 5 stars$1.80+1.1%$8.00+344.4%-31.8%$100.05M$13.03M-1.30290Upcoming EarningsNews Coverage Related Companies and Tools Related Companies VXRT Competitors OTLK Competitors INMB Competitors FENC Competitors ALVR Competitors IVVD Competitors ELUT Competitors IPSC Competitors BCAB Competitors CLLS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TROV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TROV Stock Alerts